2160
GNI Group, Inc.
2026/01/06
Consolidated subsidiary Gyre Therapeutics has completed prior consultation with China's CDE and confirmed that NDA submission utilizing the conditional approval system for F351 is possible and qualifies for priority review. NDA submission is targeted for the first half of 2026.
